空间蛋白质组学揭示非小细胞肺癌中癌基因特异性免疫微环境与预后标志物
该研究对197例非小细胞肺癌(NSCLC)肿瘤进行38标记高多重免疫荧光,按EGFR和KRAS基因型分层,分析肿瘤微环境的空间组织与免疫组成。结果显示EGFR和KRAS突变肿瘤免疫浸润减少,且各自形成独特的免疫抑制与免疫排斥微环境,空间指标与预后显著相关,提示免疫细胞定位是重要预后预测因素。
要点
- EGFR/KRAS突变NSCLC免疫浸润减少,细胞毒性T细胞、树突状细胞和粒细胞耗竭。
- EGFR突变肿瘤富集M2样肿瘤相关巨噬细胞,KRAS突变肿瘤调节性T细胞和巨噬细胞靠近肿瘤细胞。
- 空间免疫指标与预后显著相关,可指导突变导向的免疫治疗策略。
核心结论
- EGFR和KRAS突变重塑NSCLC免疫景观,形成不同的免疫抑制和免疫排斥生态位。
- 空间蛋白质组学揭示的预后免疫架构可能指导突变导向的免疫治疗策略。
研究设计与样本
- 进行定量表型分析和空间分析,包括细胞邻域、最近邻距离(5-20个细胞)和空间邻近性分析(25-100 μm),评估免疫架构与临床相关性。
主要发现
- EGFR和KRAS突变肿瘤较野生型肿瘤显示更高的肿瘤细胞密度和减少的免疫浸润。
- 两种突变均与细胞毒性T细胞、树突状细胞和粒细胞耗竭相关,EGFR突变肿瘤还富集M2样肿瘤相关巨噬细胞。
- 细胞邻域分析识别14个空间簇,突变肿瘤中富含细胞毒性T细胞和辅助T细胞的邻域减少。
- 最近邻分析显示EGFR突变肿瘤中M2样巨噬细胞间距离更短,非突变肿瘤免疫排斥更强;KRAS突变肿瘤中调节性T细胞和巨噬细胞靠近肿瘤细胞的密度更高。
- 所有空间指标在Cox比例风险模型中与预后显著相关,突显免疫细胞定位作为结局的重要预测因素。
临床怎么用
- 空间免疫指标可能用于预测NSCLC患者预后,并指导针对不同突变亚型的免疫治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Only a subset of patients with non-small cell lung cancer (NSCLC) benefit from immunotherapy, and this is partly due to limited understanding of how oncogenic mutations shape the tumor microenvironment (TME). OBJECTIVES: To define how EGFR and KRAS mutations influence the spatial organization and immune composition of the NSCLC TME. METHODS: We conducted 38-marker high-plex immunofluorescence to 197 NSCLC tumors (>2 million cells) stratified by EGFR and KRAS genotypes. Quantitative phenotyping and spatial analyses, including cellular neighborhoods (CNs), nearest neighbors (NNs = 5-20), and spatial proximity profiling (25-100 μm), were performed to assess immune architecture and clinical correlations. MEASUREMENTS AND MAIN RESULTS: EGFR- and KRAS-mutant tumors showed higher tumor cell density and reduced immune infiltration compared with wild-type tumors. Both mutation types were associated with depletion of cytotoxic T cells, dendritic cells, and granulocytes, while EGFR-mutant tumors showed enrichment of M2-like tumor-associated macrophages (TAMs). Cellular neighborhoods analysis identified 14 spatial clusters, with reduced cytotoxic and helper T cell-rich neighborhoods in mutant tumors. Nearest neighbors analysis revealed shorter distances between M2-like TAMs in EGFR-mutant tumors and greater immune exclusion in nonmutants. Spatial proximity revealed higher densities of regulatory T cells and TAMs near tumor cells in KRAS-mutant tumors. All spatial metrics correlated significantly with prognosis in Cox proportional hazards models, highlighting immune cell positioning as an important predictor of outcome. CONCLUSIONS: EGFR- and KRAS-mutant tumors remodel the NSCLC immune landscape, creating distinct immunosuppressive and immune-excluded niches. Spatial proteomics reveals prognostic immune architectures that may guide mutation-directed immunotherapy strategies.
引用
- Nandigama R, Cheikh BB, Wilhelm J, et al. Spatial proteomics profiling reveals oncogene-specific immune niches and prognostic markers in non-small cell lung cancer. Am J Respir Crit Care Med. 2026. PMID: 42363408. doi:10.1093/ajrccm/aamag330
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。